|
UNITED STATES
|
||
SECURITIES AND EXCHANGE COMMISSION
|
||
Washington, D.C. 20549
|
||
|
|
|
|
|
|
|
|
|
CURRENT REPORT
|
||
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
Revance Therapeutics, Inc.
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
001-36297
|
77-0551645
|
(State or other jurisdiction of incorporation)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
1.
|
Each of the Class III nominees of the Company’s Board of Directors were elected to hold office until the Company’s 2023 annual meeting of stockholders, as follows: Jill Beraud: 41,187,874 shares of common stock voted for and 213,246 withheld; and Robert Byrnes: 31,963,692 shares of common stock voted for and 9,437,428 withheld. There were a total of 6,301,130 broker non-votes for the election of the Class III nominees. The terms of office of Class I directors, Angus C. Russell, Phyllis Gardner, M.D. and Julian S. Gangolli, continue until the Company’s 2021 annual meeting of stockholders. The terms of office of Class II directors, Mark J. Foley, Chris Nolet and Philip J. Vickers, Ph.D., continue until the Company’s 2022 annual meeting of stockholders.
|
2.
|
The stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020, as follows: 47,178,385 shares of common stock voted for, 438,449 against, 85,416 abstaining, and no broker non-votes.
|
3.
|
The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2020 Proxy Statement, as follows: 21,647,238 shares of common stock voted for, 18,922,649 against, 831,233 abstaining, and 6,301,130 broker non-votes.
|
Date:
|
May 15, 2020
|
Revance Therapeutics, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Tobin C. Schilke
|
|
|
|
Tobin C. Schilke
|
|
|
|
Chief Financial Officer
|